Business Wire

CA-XSOLLA

16.7.2024 14:01:35 CEST | Business Wire | Press release

Share
Xsolla Launches Award-Winning Backend Solution, Adding Cross-Platform Play Support for Next-Gen Consoles

Xsolla, a global video game commerce company, announces the launch of Xsolla Backend, an innovative solution designed to help developers of all sizes, especially indie and midsize teams, work across various gaming platforms. Xsolla Backend makes their games more accessible by allowing developers to unite their audience across all platforms: PC, console, mobile, and the web. This addresses audience fragmentation common to most games and enables developers to save costs while creating deeper engagement as they grow their gaming business.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716151058/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Xsolla)

Xsolla Backend offers developers a scalable and affordable solution to enhance game functionality and player engagement across all technology platforms. This includes streamlined account management, efficient matchmaking, dynamic questing systems, and robust cross-play and multiplayer functionalities. These features ensure a more connected and immersive gaming experience, allowing developers to focus more on the creative aspects of game development while minimizing technical complexities. The vertically integrated solution enables cross-play and cross-pay across all platforms, seamlessly integrated with Xsolla game commerce solutions.

Jean-Philippe Steinmetz, Head of Xsolla Backend, states, "With Xsolla Backend, we are democratizing backend technology, ensuring developers of all sizes can access advanced tools needed to create compelling, immersive gaming experiences."

Following the strategic acquisition of the award-winning AcceleratXR technology in 2023, Xsolla Backend is designed to handle the majority of game backend needs from the outset while providing developers the flexibility to customize as needed. The platform operates on a no-upfront fee model, charging only a 5% royalty, including backend hosting, making it financially accessible and beneficial for developers of all sizes.

With over 30 active partners and more than ten in-development projects, Xsolla Backend is proving to be a game-changer in the industry. Developers interested in experiencing Xsolla Backend firsthand can demo the platform at Gamescom in Cologne this August.

David Stelzer, President of Xsolla, highlights, "Our business model and robust platform design align our success with that of our partners. Xsolla Backend is not just technology but a partnership that grows with developers, supported by ongoing enhancements and a roadmap filled with powerful updates."

Later this year, Xsolla Backend will introduce new SDKs for platforms like Microsoft Xbox and Sony PlayStation, enhancing our support for major gaming systems. The expansion will also include a self-service portal, social launcher, and updates to the admin console for more efficient game management. Developers can also look forward to integrating Xsolla Payment Systems, all of which will comply with industry regulations and maintain Xsolla's standard of regulatory adherence. Additional updates will feature a party system, gameplay collectibles, tournament systems, loot boxes, and multiplayer voice chat, further enriching the gaming experience while ensuring compliance.

For more information about Xsolla Backend or to sign up, visit xsolla.pro/xbe and Discord: xsolla.pro/xbe-discord

About Xsolla

Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.

For additional information and to learn more, please visit: xsolla.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240716151058/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye